Discriminación entre hiperplasia prostática benigna y cáncer de próstata mediante el uso de PSA index en consulta externa de urología

We suggest a PSA index of 17% as cut-off point to discriminate between benign prostatic hyperplasia and prostate cancerin the urology outpatient consult of patients with a total PSA between 4.0 ng/ml and 9.9 ng/ml. We recommend this value as it could reduce the number of negative biopsies.